



CONFERENCE BROCHURE

Discovery 2024 & Automate 2024

22 - 23 May 2024 | Basel, Switzerland

Bringing together 500+ key experts in the field of drug discovery screening, target identification, validation & neuroscience drug development. Oxford Global's Discovery Europe 2024, features the 22nd Annual Drug Discovery Summit & Discovery Chemistry Europe Congress and the 5th Annual Neuroscience Drug Development Congress. The co-located Automate 2024 featuring 3rd Annual SmartLabs Automation and Robotics Congress stands as the foremost venue to explore cutting-edge advancements in smartlabs automation and mobile robotics.

Key Speakers Include



DAVIDE GIANNI
Senior Director, AstraZeneca



JEFF MESSER
Director Analytics, GSK



SANDRINE DESSOY,
Innovation Advisor,
GSK



REKHA LAKSHMANAN,
Global Head Of Data Office,
AstraZeneca



CHARLY COULON, Head of
Future Manufacturing
Concepts, INVITE GmbH



STEVEN DRIVER,
Global Energy
Leader,
Sanofi



BIANCA BRENNER, Head of
MES Projects,
Bayer



George Karageorgis,
Senior Scientist,
AstraZeneca



JOHAN LUTHMAN, Executive
Vice President of R&D,
Lundbeck



SANNE GLAD, Scientific
Director, Amgen Research
Copenhagen

Book Now 

More Information:

oxfordglobal.com/discovery/events/discovery-europe-2024
oxfordglobal.com/discovery/events/automate-europe-2024

 @OGConferences

 LinkedIn



WELCOME TO

Discovery Europe 2024 & Automate 2024

On behalf of the entire Oxford Global team, I am delighted to welcome you to **Discovery 2024 & Automate 2024**. From new and exciting innovations to the latest in products and services, our event will bring together leading companies for engaging discussions, knowledge sharing and focused networking.

The Oxford Global team look forward to meeting you over the course of the event and will be on hand to ensure your time is both productive and enjoyable.

Oxford Global Marketing Ltd. has been producing cutting edge congresses and summits for the Life Sciences Industry for over 16 years. I am pleased to let you know that we have now successfully completed a transition from an in-person event organiser to one stop shop platform for all research-critical information pertaining to the Discovery space. We would like to invite you to visit our [Discovery Content Portal](#) to find out more about our brand-new membership offering, giving you access to the latest technology insights and research community we have been building over the last 16 years. You can register for the newsletter to get updates on upcoming activities within this series, stay up to date with industry news and more.

The event is designed to provide a comprehensive look at the current trends, challenges and developments impacting the sector. For a detailed breakdown of the areas we will discuss, please see the Session Topic Areas page, and use the Full Programme Agenda to identify which of our expert presentations are of the highest interest to you.

We want to create an environment where attendees can converse in smaller groups, so the programme will host a series of engaging discussions such as panels and workshops to encourage as much knowledge-sharing as possible.

We are hugely thankful to our speakers, who have given their time to provide interesting, thought-provoking presentations, and to our sponsoring companies, who have worked closely with us to provide you with unique opportunities to access the latest information on solutions and services that can directly impact and improve your research and results. Without their support this event would not be possible, so please do take some time to visit their stands in-person and featured sponsor pages on the event app (Swapcard). Once again, welcome to the event — we hope it will prove to be both educational and enjoyable for you.

Charlotte Catley,
Sponsorship Director



- Welcome
- Attendees
- Sponsors
- Session Topic Areas
- Programme Highlights
- Confirmed Speakers
- Agenda: Day One
- Agenda: Day Two
- Venue Information
- Networking Drinks
- Oxford Global Plus Pass
- Forthcoming Events

Book Now

Network and Knowledge-Share

500+ VPs, Directors & Senior Managers will be on-site, coming from leading healthcare, biotech, pharma and research institutions in the following fields & more:


- Medicinal Chemistry
 - Chemical Biology
 - Drug Design
 - Drug Discovery
 - Target Discovery
- Process Chemistry
 - Neurotechnology
 - Neuropharmacology
 - Drug Screening
 - Organoid Development
- Lab Automation
 - Lab Digitisation
 - Mobile Robotics
 - HTE
 - AI/ML
- SmartLabs
 - Data Science
 - Digital Twins
 - In Silico Models
 - Workflow Automation

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Formal 1-2-1 meeting opportunities will be available to arrange prior to the event which take place during the dedicated refreshment (networking) breaks covering:

- Protein Degradation Tools
 - Screening Technologies
 - Library Optimisation
 - Target Validation
 - Neuroengineering Tools
- Neuroinformatic Tools
 - Discovery IT
 - Protein Degradation
 - Assay Development
 - Organoid Discovery
- Robotics Software
 - Workflow Automation
 - Lab Automation
 - Smart Manufacturing
 - Robotic Automation
- Data Management
 - Data Analytics
 - Data Integration
 - Autonomous Mobile Robots
 - Digital Tools

Previous Attendee Profile

(Stats from Discovery Europe 2023)



Attended by these companies & many more:



Welcome

Attendees

Sponsors

Session Topic Areas

Programme Highlights

Confirmed Speakers

Agenda: Day One

Agenda: Day Two

Venue Information

Networking Drinks

Oxford Global Plus Pass

Forthcoming Events

Book Now

WHO IS SPONSORING?

Drive Innovation & Accelerate Research

Gold Sponsors



Silver Sponsors



Bronze Sponsors



Network & Programme Sponsors



For sponsorship enquiries, please
contact sponsorship@oxfordglobal.com

BROCHURE CONTENTS

Welcome

Attendees

Sponsors

Session
Topic Areas

Programme
Highlights

Confirmed
Speakers

Agenda:
Day One

Agenda:
Day Two

Venue
Information

Networking
Drinks

Oxford
Global
Plus Pass

Forthcoming
Events

Book Now

LinkedIn

@OGConferences

Explore Curated & Insightful Content

Discovery Europe 2024 features **2 days** of in-person cutting-edge presentations and knowledge-sharing, including **over 100** industry insights, sponsored presentations & think tank roundtable discussions.

Day One | 22 May 2024

Conference Room 1: Identification & Validation of Novel Targets

- New modalities & emerging drug targets in oncology, immuno-oncology and other disease areas
- AI to unblock drug discovery, drug repurposing and target validation
- Identification and validation of novel targets
- Discovery of 1st class inhibitors
- Induced proximity- RNA, Targeted RNA via small molecules
- Cellular and biological based drug discovery
- Digitisation & AI Approaches featured session

Conference Room 2: Identification & Validation - Targeted Protein Degradation

- Targeted Protein Degradation And Target Validation
- Induced Proximity and Protein Degradation in Drug Discovery
- Novel Strategy to Induce the Degradation of a Target Protein
- Assay Technology Development & Tools

Conference Room 3: Advanced Screening Approaches & Enabling Technologies

- Fast structure-based virtual screening in readily available chemical space
- Phenotypic screen in primary dendritic cells to identify new targets
- New technologies for target and phenotypic based discovery including spatial analysis
- Functional genomics approaches in drug discovery
- Target and Phenotypic Based Discovery including Functional Screening
- Affinity based Screening approaches
- Virtual Screening -Ligand vs structured based screening

Conference Room 4: Advances In Medicinal Chemistry, Drug Design

- AI & Automation in chemical synthesis
- Efficient combination of machine learning and automation to accelerate DMTA cycles
- Measuring PK/PD and prediction of response AI in Chemical Synthesis
- Lead Optimisation
- Predicting PK/PD and predictive cellular modelling
- Exploring the Chemical space – effective search of the space- finding the best way
- Advances in Antibodies drug design
- Quantum Based Drug Design

Conference Room 5: Therapeutic Strategies, Enabling Technologies & Biomarker Development

- Advancements and emerging trends in the application of technology in developing neurological treatments
- Neuroscience biomarker development
- Translational approaches for drug discovery
- Opportunities and challenges of designing and implementing targeted diagnostics and therapeutics
- The blood brain barrier in CNS diseases
- AI, digital and Imaging strategies for Biomarker development

Day Two | 23 May 2024

Conference Room 1: Emerging Modalities of Drug Discovery- Targeted Protein Degradation

- Targeted Protein Degradation/ Molecular Glues
- Addressing Challenging Targets
- E3 Ligase Discovery

Conference Room 1, Part 2: Animal Models for Disease, Organ Modelling - Organoid Based Discovery & Organ On Chip Development

- Animal Models for Disease
- Translating breakthrough discoveries in stem cell biology and organ development
- Utilisation of 3D-model systems and organoids in phenotypic and high content screening
- Modelling protein aggregation in human iPSC
- 3D media and 3D cell culture
- Safety and efficacy considerations
- Digitisation & AI Approaches featured session

Conference Room 2: Molecular Drug Design & Hit Finding/ Optimisation

- Fragment & structured based drug discovery innovation including AI/ ML driven approaches
- Innovating the chemistry lab bench
- Digitisation & AI Approaches featured session
- Showcase of hit-to-lead components & technologies e.g. targeted protein degradation, covalent inhibitors, DELs
- Case studies of lead generation in small and large molecules
- Enabling tools for hit-finding against difficult targets
- Applications of covalent fragments to drug lead generation
- Biophysical tools for difficult targets: building the right flow chart

Conference Room 3: Drug Discovery for Neurodegenerative Diseases

- Target identification and validation approaches
- Neurodegenerative, and Neuroinflammation/Immunology models for robust drug discovery
- Stem cell technology to fuel drug discovery
- iPS cells for disease modelling and drug discovery
- In vitro and in vivo disease modelling
- Targeting and regulating neuroinflammation

Welcome

Attendees

Sponsors

▶ Session
Topic AreasProgramme
HighlightsConfirmed
SpeakersAgenda:
Day OneAgenda:
Day TwoVenue
InformationNetworking
DrinksOxford
Global
Plus PassForthcoming
Events

Book Now

Explore Curated & Insightful Content

Automate Europe 2024 features **2 days** of in-person cutting-edge presentations and knowledge-sharing, including **over 100** industry insights, sponsored presentations & think tank roundtable discussions.

Day One | 22 May 2024

Conference Room 6: Bridging The Gap Between Automation & Digitalisation through FAIR & Digital Transformation

Part 1 – Lab Digitalisation via Automation, Lab Process Optimisation & Efficiency

- Building a digital and cost-effective lab (R&D, QC)
- Adoption of digital tools & technologies in labs
- Paperless labs, LIMS, ELNS integration
- Maximising system's efficiency in the lab:
 - » Developing softwares & hardwares for automated systems
 - » Lab analysis methods
 - » Cloud-based systems
- State-of-the art devices to integrate multiple lab techniques into a system: microfluidics – lab-on-a-chip

Part 2 – Data FAIRification

- FAIR data management in labs of the future
- Improving reproducibility
- Enhancing lab connectivity for streamlined FAIR data capture

Conference Room 7: Smart Manufacturing & Robotics

- Developing digital twins
- Implementation of a digital strategy
- Process control & optimization of manufacturing processes
- Hybrid modelling and in silico model development
- Deploying QbD and PAT from R&D to manufacturing processes
- Development of future mobile robotics in drug development
- Manufacturing, Production & Logistics of Mobile Robots
- Manufacturing of mobile robots
- Application of mobile robots in QA & QC environments
- Autonomous mobile robots in smart manufacturing

Day Two | 23 May 2024

Track 4, Part 1: Data-Driven Modelling & Data Analytics for Drug Discovery & Development

- Building predictive & generative modelling
- Multi-modal data integration
- Quantum computing
- Leveraging Big Data

Track 4, Part 2: Automation with AI/ML & Robotics Tools in Drug Discovery & Development

- Lab robotics & tools for drug discovery workflows:
 - » Automated liquid handlers
 - » Microplate readers
 - » Data visualisation tools
- Implementing AI/ML in the lab
- Robotic process automation
- Maximizing R&D through cloud-based control and automation of scientific workflows
- Potency assays

Welcome

Attendees

Sponsors


Session
Topic Areas► Programme
HighlightsConfirmed
SpeakersAgenda:
Day OneAgenda:
Day TwoVenue
InformationNetworking
DrinksOxford
Global
Plus PassForthcoming
Events

Book Now

Connect with Industry Influencers

Attracting leading experts & the brightest minds in the industry to educate, inform and excite our attendees.

Presentation highlights include:




JOHAN LUTHMAN, Executive Vice President of R&D, Lundbeck

Day One

08:50

The Landscape And Breakthrough In Neuroscience




SANNE GLAD, Scientific Director, Amgen Research Copenhagen

Day One

08:50

E3 Ligase Novel Binder Identification And Their Use Across Various Platforms




ANNA VULPETTI, Associate Director, Novartis

Day Two

12:20

Integration HIT Finding Approaches For Difficult/Novel Targets




SANDRINE DESSOY, INNOVATION ADVISOR, GSK

Day Two

12:20

Revolutionizing Analytical Method Development Using Prior Knowledge And Automation




STEVEN DRIVER, Global Energy Leader, Sanofi

Day One

08:50

Maintaining Energy And Sustainability In The Manufacturing Environment




GEORGE KARAGEORGIS, Senior Scientist - Data, Automation, Robotics, AstraZeneca

Day One

09:10

Implementation Of A Digital Strategy Using Open Source Tools




CHARLY COULON, Head of Future Manufacturing Concepts, INVITE GmbH

Day One

09:10

Application Of Digital Twins In Vaccine Process Development & Manufacturing



BIANCA BRENNER, Head of MES Projects, Bayer

Day One

15:50

Integration Of IPC Equipment Into MES To Enable Paperless Production

Programme Highlights

Interactive Sessions

- ✓ Panel Discussion: Landscape Of Drug Discovery And Impact Of AI
- ✓ Workshop: Overcoming The Blood Brain Barrier In The Delivery Of Therapeutics
- ✓ Panel Discussion: Emerging Modalities & Overcoming Challenges
- ✓ Panel Discussion: Automation & Robotics In Drug Discovery & Development – Where Are We Now?

Key Presentations

- ✓ AI/ML In Drug Discovery: DNA Encoded Libraries Use Case
- ✓ Functional Genomic Tools For Elucidating Novel Targets
- ✓ Regulation Of Neuroinflammation In Neurodegenerative Diseases
- ✓ Advanced Manufacturing Technologies For Mobile Robots

Welcome

Attendees

Sponsors

Session Topic Areas

▶ Programme Highlights

Confirmed Speakers

Agenda: Day One

Agenda: Day Two

Venue Information

Networking Drinks

Oxford Global Plus Pass

Forthcoming Events

Book Now

Gain Expertise from Thought Leaders

DAY ONE

GREG HOLLINGWORTH

Director, Chemistry and TPD/Proximity Initiative Co-Lead, Novartis

FLORENT SAMAIN

Principal Research Scientist II, AbbVie

JEFF MESSER

Director Analytics, GSK

JAMES OVERELL

Group Medical Director, Roche

DAVIDE GIANNI

Senior Director, AstraZeneca

SANNE GLAD

Scientific Director, Amgen Research Copenhagen

THOMAS ULLRICH

Director Medicinal Chemistry, Novartis

OLIVER HUCKE

Associate Director, Chemistry (CNS Diseases), Boehringer Ingelheim

BALAZS FORIZS

Head of Biochemistry & Biophysics, Cantabio Pharmaceuticals

NILS HANSEN

Chief Executive Officer, Vipergen

BERENGERE DUMOTIER

Associate Director, Novartis

IRENE CHOI

Head of Drug Discovery, Verge Genomics

NATHALIE CARTIER-LACAVE

Senior Vice President Neurobiology, Askbio

TAKHAR KASUMOV

Associate Professor of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University

OLIVIER LOISELEUR

Senior Team Leader, Syngenta

ULRICH LÜCKING

Vice President, Head of Chemistry, FoRx Therapeutics AG

PAULINA KOLASINSKA-ZWIERZ

Principal Scientist, Alchemab Therapeutics

XIANG YI

Senior Principal Scientist, Amgen

JONATHAN MASON

Senior Research Advisor, Design for Drug Discovery

GEOFFREY KERCHNER

Vice President, Global Head of Early Development – Neuroscience & Rare Diseases, Roche

KERSTIN HOFER

Senior Scientist & Matrix Lead, Roche

URS LANGEN

Lab Head, Roche

EMMA DAVIES

Associate Director, Healx

JON LEA

Team Leader, GSK

ROBIN LÖVING

Chief Scientific Officer, Salipro Biotech

CARL POELKING

Associate Director, Astex

SIMON HUET

Senior Scientist, Affilogic

OLIVIER BUGAUD

Senior Scientist Assay Development, Galapagos

CHANNABASAVAIAH GURUMURTHY

Professor and Director, University of Nebraska Medical Center

AMELIE JOFFRIN

Investigator, GSK

STEVEN DRIVER

Global Energy Leader, Sanofi

NIKOLAOS PAPAKOSTAS

Professor, University College Dublin

ELIAS HAGMANN

Senior Manager Data Science & Information Architecture, Molecular Partners AG

GEORGIOS MAVRAKIS

Senior Associate Scientist, Johnson & Johnson

GEORGE KARAGEORGIS

Senior Scientist - Data, Automation, Robotics, AstraZeneca

ALASTAIR FLORENCE

Professor & Director of the EPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation, University Of Strathclyde

TOM KISSLING

pRED Lab Automation Partner, F. Hoffmann La Roche Ltd

BART VAN LOON

Lab Information & Automation Specialist, MSD

SANDRINE DESSOY

Innovation Advisor, GSK

Welcome

Attendees

Sponsors

Session Topic Areas

Programme Highlights

Confirmed Speakers

Agenda: Day One

Agenda: Day Two

Venue Information

Networking Drinks

Oxford Global Plus Pass

Forthcoming Events

Book Now

Gain Expertise from Thought Leaders

CHARLY COULON
Head of Future Manufacturing Concepts, INVITE GmbH

JAMIE CLIFTON
Senior Scientist, Roche

BIANCA BRENNER
Head of MES Projects, Bayer

MARKUS HUNGENBACH
Program Manager MES Global Program, Bayer

MICHAEL ANGELO AMITH FENELON
Mechatronic Engineer, NMBU

RAUL V. RODRIGUEZ
Vice President, Woxsen University

DAY TWO

SIMONA COTESTA
Director Global Discovery Chemistry, Novartis

JANET BROWNLEES
Senior Director, Merck Sharpe and Dohme

GREGORI GEREBTZOFF
Director, Novartis

DANIEL SEELIGER
Head of Small Molecule Design, Exscientia

MORTEN GRUNNET
Vice President & Head of Neuroscience, Lundbeck

ARIANNA SABÒ
Head of R&D, Quantro Therapeutics GmbH

ROBERT FREMEAU
Chief Scientific Officer and Founder, BrainStorm Therapeutics

ANTO PAVLOVIC
Principal Research Associate, Roche

JULIAN RÖWE
Senior Scientist, AbbVie

MARKUS SCHADE
Senior Scientist for NMR Fragment Screening, Astra Zeneca

FILIP ROUDNICKY
Senior Principal Scientist, Group Leader Cellular Engineering, Lead Discovery, Therapeutic Modalities, F. Hoffmann-La Roche

ANNA VULPETTI
Associate Director, Novartis

ULRIKE KUNZEL
Associate Principal Scientist, Astra Zeneca

ERIC GOEDKEN
Senior Principal Scientist, AbbVie

XINXIN GAO
Principal Scientific Manager, Genentech

ADRIANA SAVOCA
Associate Director, Translational PKPD, AstraZeneca

JEAN-PHILIPPE ROCHER
Head of Discovery, Chemistry, Neurosterix

GRAHAM DEMPSEY
Chief Scientific Officer, Quiver Bioscience

DAOHONG ZHOU
Professor and Director, Center for Innovative Drug Discovery, University of Texas Health San Antonio

PETER BRANDT
Head Of Chemistry, Beactica Therapeutics

BORISLAV DEJANOVIC
Director – Translational Sciences & External Innovation, Vigil Neuroscience

HAI RAO
Professor & Chair, Southern University of Science & Technology

HENRIK MÖBITZ
Associate Director, Novartis

DAVID BEARSS
Chief Executive Officer, Halia Therapeutics

GIOVANNI SPAGNOLLI
Chief Technology Officer, Sibylla Biotech

GEBHARD THOMA
Associate Director, Novartis

ALEXANDRA PHILLIPS
Translation Programme Manager, UK Dementia Research Institute

EILEEN WEGNER
Research Associate, NMI

PATRIK KAGELID
Data Engineer, AstraZeneca

CK ONG
Director, Data Product, GSK

VERA JOST
Principal Associate Scientist, F.Hoffmann-La Roche

Welcome

Attendees

Sponsors

Session Topic Areas

Programme Highlights

Confirmed Speakers

Agenda: Day One

Agenda: Day Two

Venue Information

Networking Drinks

Oxford Global Plus Pass

Forthcoming Events

Book Now

CONFIRMED SPEAKERS

Gain Expertise from Thought Leaders

GEORG WUITSCHIK
Senior Principal Scientist, F.Hoffmann-La Roche

PAOLA FERRINI
High Throughput Automation Investigator, GSK

JULIE FOURNIER
Senior Scientist, GSK

FELIX STEMMER
Senior Scientist II, Novartis

PRANAV BENDE
Senior Robotics Engineer, National Institutes Of Health

DALVIN DEOL
Automation and Modelling Expert, GSK

ASMITA AGRAWAL
Group Manager, Novo Nordisk

OLIVER DE PEYER
Automation Scientist, MeiraGTx

BROCHURE
CONTENTS

Welcome

Attendees

Sponsors

Session
Topic Areas

Programme
Highlights

Confirmed
Speakers

Agenda:
Day One

Agenda:
Day Two



Venue
Information

Networking
Drinks

Oxford
Global
Plus Pass

Forthcoming
Events

Book Now

DAY ONE						
08:30	Oxford Global Welcome Address <i>(Taking place in Conference Rooms 1, 2, 5, 6, & 7)</i>					
DISCOVERY EUROPE 2024				AUTOMATE EUROPE 2024		
CONFERENCE ROOM 1: IDENTIFICATION & VALIDATION OF NOVEL TARGETS	CONFERENCE ROOM 2: IDENTIFICATION & VALIDATION - TARGETED PROTEIN DEGRADATION	CONFERENCE ROOM 5: THERAPEUTIC STRATEGIES, ENABLING TECHNOLOGIES & BIOMARKER DEVELOPMENT	CONFERENCE ROOM 6: BRIDGING THE GAP BETWEEN AUTOMATION & DIGITALISATION THROUGH FAIR & DIGITAL TRANSFORMATION	CONFERENCE ROOM 7: SMART MANUFACTURING & ROBOTICS		
<p>Keynote Address: Synergies Of Screening Strategies To Improve Small Molecule Hits Identification Success</p> <ul style="list-style-type: none">The drug discovery toolbox has expanded considerably with the development of new affinity screening techniques. Each of these techniques has its strengths and liabilities. The presentation will discuss how to leverage two screening strategies through a case study <p>FLORENT SAMAIN, Principal Research Scientist II, AbbVie</p>	<p>Keynote Address: E3 Ligase Novel Binder Identification And Their Use Across Various Platforms</p> <ul style="list-style-type: none">Amgen is expanding the scope of Targeted Protein Degradation by tapping into the vast E3 ligase space, utilizing our strong DEL technology platform for discovering novel ligase bindersOur E3 ligand and fragment database now covers 26 ligases and enables multiple successful degrader/glue discovery platforms, which will be briefly presented <p>SANNE GLAD, Scientific Director, Amgen Research Copenhagen</p>	<p>Keynote Address: The Landscape And Breakthrough In Neuroscience</p> <ul style="list-style-type: none">In recent years, neuroscience drug discovery has surged, validating new compounds and repositioning old ones, expanding therapy options. Neuroscience now ranks high in drug approvals, spanning diverse modalities. Pharma, once disengaged, is now reinvesting, foreseeing potential. Previously untreatable neurological conditions now have effective therapies. Emerging innovative drug targets promise further advancements ahead <p>JOHAN LUTHMAN, Executive Vice President of R&D, Lundbeck</p>	<p>Keynote Address: Application Of Digital Twins In Vaccine Process Development & Manufacturing</p> <ul style="list-style-type: none">The talk focuses on the development and use of Digital Twins by GSK for the development and control of vaccines production process. Development strategy will be discussed, examples of digital twin will be presented for batch and continuous processes <p>SANDRINE DESSOY, Innovation Advisor, GSK</p>	<p>Keynote Address: Maintaining Energy And Sustainability In The Manufacturing Environment</p> <ul style="list-style-type: none">The presentation "Maintaining Energy and Sustainability in the Manufacturing Environment" shares Sanofi's energy and environmental goals, program, and roadmap including process optimization. Maintaining a sustainable future combining AI with energy management systems is also reviewed. The second part of the presentation focuses on Sanofi's recent continuous manufacturing facility <p>STEVEN DRIVER, Global Energy Leader, Sanofi</p>		
CONFERENCE ROOM 1: IDENTIFICATION & VALIDATION OF NOVEL TARGETS	CONFERENCE ROOM 2: IDENTIFICATION & VALIDATION - TARGETED PROTEIN DEGRADATION	CONFERENCE ROOM 3: ADVANCED SCREENING APPROACHES & ENABLING TECHNOLOGIES	CONFERENCE ROOM 4: ADVANCES IN MEDICINAL CHEMISTRY, DRUG DESIGN	CONFERENCE ROOM 5: THERAPEUTIC STRATEGIES, ENABLING TECHNOLOGIES & BIOMARKER DEVELOPMENT	CONFERENCE ROOM 6: BRIDGING THE GAP BETWEEN AUTOMATION & DIGITALISATION THROUGH FAIR & DIGITAL TRANSFORMATION	CONFERENCE ROOM 7: SMART MANUFACTURING & ROBOTICS
<p>Track Chair: AMELIE JOFFRIN, Investigator, GSK</p>	<p>Track Chair: RICHARD LEWIS, Director Data Science, Novartis</p>	<p>Track Chair: TAKHAR KASUMOV, Associate Professor of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University</p>	<p>Track Chair: BARTOSZ BARANOWSKI, Senior Expert Data Science, Novartis</p>	<p>Track Chair: AURELIE LE FEUVRE, Senior Principal Scientist, BenevolentAI</p>	<p>Track Chair: PATRIK KAGELID, Data Engineer, AstraZeneca</p>	<p>Track Chair: RAUL V. RODRIGUEZ, Vice President, Woxsen University</p>
<p>Track Keynote Address: Functional Genomic Tools For Elucidating Novel Targets</p> <ul style="list-style-type: none">Target selection is the first and most important decision we take in the drug discovery and development process. I will illustrate some of the key challenges and opportunities we have in Target Discovery in industry and how early adoption of a collaborative mind set, AI and machine learning and integrating genome editing and automation capabilities can help address themA couple of case studies will be presented to exemplify target discovery capabilities outside of just the Target Identification and Validation process <p>DAVIDE GIANNI, Senior Director, AstraZeneca</p>	<p>Track Keynote Address: Molecular Glue, DELs And Protein Degradation</p> <ul style="list-style-type: none">DELs in CellsMultiplexingMolecular glue direct screen <p>NILS HANSEN, Chief Executive Officer, Vipergen</p>	<p>Track Keynote Address: From Phenotypic Screening To Target Identification - A Case Study</p> <ul style="list-style-type: none">Phenotypic screening delivered two small molecules capable of inducing tendon repair mechanisms by upregulating the expression of tenogenic markers in cells. Using state-of-the art chemical biology and pharmacophore-guided medicinal chemistry, we identified the primary molecular target of those phenotypic hits. Preliminary in vivo pharmacology and toxicology studies will be presented <p>THOMAS ULLRICH, Director Medicinal Chemistry, Novartis</p>	<p>Track Keynote Address: AI/ML In Drug Discovery: DNA Encoded Libraries Use Case</p> <ul style="list-style-type: none">DNA Encoded Libraries (DELs) are invaluable in small molecule drug discovery, providing vast datasets efficiently. By properly leveraging this data, machine learning models can predict drug-target interactions, identify novel compounds, and optimize drug design. This integration accelerates drug discovery, leading to more efficient and targeted therapeutic interventions <p>JEFF MESSER, Director Analytics, GSK</p>	<p>Track Keynote Address: Digital Biomarkers For Multiple Sclerosis</p> <ul style="list-style-type: none">Clinical digital biomarkers offer the opportunity to meaningfully reflect daily impairment in MS, and to measure that impairment accurately. Both passive and active measurements bring considerable challenges. Using a measure during a clinical development program requires clarity regarding its purpose, and judgement regarding its ability to meet that purpose <p>JAMES OVERELL, Group Medical Director, Roche</p>	<p>Track Keynote Address: Implementation Of A Digital Strategy Using Open Source Tools</p> <ul style="list-style-type: none">The implementation of digital strategies is heavily dependent on the availability of appropriate tools making processing and sharing data to non-experts possible. I am demonstrating an example where open-source tools are used to deploy web applications which simulate chemical processes facilitating a data-first process design and optimisation strategy <p>GEORGE KARAGEORGIS, Senior Scientist - Data, Automation, Robotics, AstraZeneca</p>	<p>Track Keynote Address: Automated Supply In Pharmaceutical Packaging Of The Future</p> <ul style="list-style-type: none">The current state of the art does not allow for the economical automation of material supply for secondary packaging~20 pharmaceutical companies, packaging machine manufacturers and automation specialists therefore joined forces to develop a disruptively simpler solution conceptThe presentation presents the result and the planned implementation <p>CHARLY COULON, Head of Future Manufacturing Concepts, INVITE GmbH</p>
09:30	<div>MORNING BREAK</div> <div> 1-2-1 Meetings x4</div> <div> Poster Displays</div>					

BROCHURE CONTENTS

Welcome

Attendees

Sponsors

Session Topic Areas

Programme Highlights

Confirmed Speakers

▶ Agenda: Day One

Agenda: Day Two

Venue Information

Networking Drinks

Oxford Global Plus Pass

Forthcoming Events

Book Now

10:50	<div>CONFERENCE ROOM 1: IDENTIFICATION & VALIDATION OF NOVEL TARGETS</div> <div>Enhancing Drug Discovery With Human-Centric Generative AI</div> <div><ul style="list-style-type: none">Discover with Causaly's Scientific Specialist, Sarah Ateaque, PhD, the groundbreaking ways Generative AI is being applied in target identification and validation. Step into the shoes of discovery scientists and see firsthand how GenAI is changing and accelerating research workflows</div> <div>SARAH ATEAQUE, Scientific Specialist, Causaly</div> <div></div>	<div>CONFERENCE ROOM 3: ADVANCED SCREENING APPROACHES & ENABLING TECHNOLOGIES</div> <div>De-Risked Hit Finding And Orthogonal Triaging Through Mass Spectrometry</div> <div><ul style="list-style-type: none">Pivot Park Screening Centre (PPSC) incorporated Affinity Selection Mass Spectrometry (ASMS) into its high-throughput screening operations, enhancing the study of protein-ligand interactions. This label-free, high-throughput compatible method allows for efficient screening of large compound libraries without the need for mobilization or extensive assay development</div> <div>SAMAN HONARNEJAD, Chief Scientific Officer, Pivot Park Screening Centre</div> <div></div>	<div>CONFERENCE ROOM 4: ADVANCES IN MEDICINAL CHEMISTRY, DRUG DESIGN</div> <div>Delegates welcome to attend co-located sessions</div>	<div>CONFERENCE ROOM 5: THERAPEUTIC STRATEGIES, ENABLING TECHNOLOGIES & BIOMARKER DEVELOPMENT</div> <div>Delegates welcome to attend co-located sessions</div>	<div>CONFERENCE ROOM 6: BRIDGING THE GAP BETWEEN AUTOMATION & DIGITALISATION THROUGH FAIR & DIGITAL TRANSFORMATION</div> <div>Delegates welcome to attend co-located sessions</div>	<div>CONFERENCE ROOM 7: SMART MANUFACTURING & ROBOTICS</div> <div>Solution Provider Presentation</div> <div>Senior Representative, Omron</div> <div></div>
11:10	<div>The Use Of CETSA® In Physiological Relevant Drug Discovery</div> <div><ul style="list-style-type: none">Many therapeutical relevant drug targets remain undrugged because we lack tools to prosecute them. Through a number of use cases stretching from Target Identification to validation of Lead Series we illustrate how applications of the CETSA® technology opens up novel target space</div> <div>STINA LUNDGREN, Head of Business Development, Pelago Bioscience</div> <div></div>	<div>Biophysical And Structural Biology Methods Enable Fragment-Based Ligand Discovery</div> <div><ul style="list-style-type: none">Powerful biophysical and structural biology tools enable the study of large numbers of fragments and are opening up new possibilities in the treatment of various diseases. Here we report the results of a conventional and a covalent Fragment Screening and show how orthogonal biophysical and structural methods enable rapid identification, characterization, and optimization of fragments</div> <div>MORAN JERABEK-WILLEMSSEN, Head of Biophysics & Screening, Crelux GmbH - A WuXi AppTec Company</div> <div></div>	<div>Accelerating Drug Discovery With AI And Next-Generation Automation</div> <div><ul style="list-style-type: none">This presentation delves into the transformative impact of AI and automation on drug discovery, focusing on XtalPi's unique approach that blends AI with physics-based methods for precise exploration of chemical space. Through case studies, we'll demonstrate how XtalPi's tailored AI and automation approach drives innovation and efficiency in specific drug discovery projects</div> <div>ZHIXIONG LIN, Director of AIDD, XtalPi</div> <div></div>	<div>Next-Generation Multi-Omics To Accelerate Drug Discovery & Development</div> <div><ul style="list-style-type: none">How dynamic biomarkers – including metabolites, lipids, and proteins – complement and extend genomics data for novel insights into disease mechanisms, target identification, and drug responseHow next-generation mass spectrometry technologies are enabling rapid, high throughput multi-omics biomarker discovery, measuring thousands of these biomarkers in every sample, across thousands of samples at a timeHow this multi-omics data is integrated using AI/ ML tools to derive actionable insights that can accelerate development of protein degraders, T cell engagers, gene therapies, and other innovative drug modalities</div> <div>MO JAIN, Founder and Chief Executive Officer, Sapient</div> <div></div>	<div>Delegates welcome to attend co-located sessions</div>	<div>Translating Evolving Portfolio Into Device Assembly Equipment Solutions - A Case Study On Modular Robotic Automation</div> <div><ul style="list-style-type: none">Roche recognised the need for a modular and flexible production solution in light of the increasing importance of devices and the trend towards smaller volumes and more configurations. ESSERT has risen to this challenge and developed a flexible, modular and scalable production line</div> <div>MORITZ LATZEL, Chief Scientific Officer & PHILIP SCHNEIDER, Drug Product Manufacturing Network Technology Lead, Essert Robotics; Roche</div> <div></div>
11:30	<div>Harnessing The Synergy Between Biophysics And Biochemistry To Drive Drug Discovery</div> <div><ul style="list-style-type: none">The analysis of protein-protein interactions (PPIs) is challenging and can suffer from various limitations. Here we present a case study where we combined biochemical and biophysical technologies to set up a highly sensitive, robust and high throughput assay to drive SAR and support drug discovery</div> <div>OLIVIER BUGAUD, Senior Scientist Assay Development, Galapagos</div>	<div>Cell Engineering And CRISPR Genetic Screening In Physiological Models</div> <div><ul style="list-style-type: none">Employing CRISPR/Cas9 in hPSCs, this talk examines AKT2's impact on endothelial dysfunction. It also presents a CLDN5 reporter for screening compounds that fortify endothelial cell barrier and details a nucleofection method in iPSC-derived immune cells to find lipid metabolism regulators</div> <div>FILIP ROUDNICKY, Senior Principal Scientist, Group Leader Cellular Engineering, Lead Discovery, Therapeutic Modalities, F. Hoffmann-La Roche</div>	<div>Designing Drug-Like High Affinity Ligands For A TPP-Orthogonal Riboswitch</div> <div><ul style="list-style-type: none">Using structure-based design, a drug-like nanomolar affinity ligand for a riboswitch was obtained that modulates a redesigned switch rendered insensitive to its natural substrate TPP. Such systems could find applications in next-generation gene therapies</div> <div>OLIVER HUCKE, Associate Director, Chemistry (CNS Diseases), Boehringer Ingelheim</div>	<div>Identifying Pharmacological Chaperones As Disease Modifying Therapeutic Candidates For Alzheimer's And Parkinson's Disease</div> <div><ul style="list-style-type: none">Structure-biology basis of the interaction between small molecules and intrinsically disordered proteins introducedIdentification of small molecule binders of intrinsically disordered proteins, such as α-synuclein and tau, using unique computational structure-based or biophysics based high-throughput screening approachesApplication of pharmacological chaperones in Alzheimer's and Parkinson's disease</div> <div>BALAZS FORIZS, Head of Biochemistry & Biophysics, Cantabio Pharmaceuticals</div>	<div>Panel Discussion: Automation & Robotics In Drug Discovery & Development – Where Are We Now?</div> <div>Moderator: GEORGIOS MAVRAKIS, Senior Associate Scientist, Johnson & Johnson Panellists: PAOLA FERRINI, High Throughput Automation Investigator, GSK NIKOLAOS PAPAKOSTAS, Professor, University College Dublin OLIVER PETER, President, SiLA Consortium</div>	<div>Panel Discussion: Navigating The Future Of Manufacturing: Insights On Smart Manufacturing And Industry 4.0</div> <div>Moderator: REKHA LAKSHMANAN, Global Head Of Data Office, AstraZeneca Panellists: DALVIN DEOL, Automation and Modelling Expert, GSK STEVEN DRIVER, Global Energy Leader, Sanofi ARNDT NEUES, Industry Sales Manager, Omron</div>

BROCHURE CONTENTS

Welcome

Attendees

Sponsors

Session Topic Areas

Programme Highlights

Confirmed Speakers

Agenda: Day One

Agenda: Day Two

Venue Information


Networking Drinks






Oxford Global Plus Pass

Forthcoming Events

Book Now

CONFERENCE ROOM 1: IDENTIFICATION & VALIDATION OF NOVEL TARGETS	CONFERENCE ROOM 3: ADVANCED SCREENING APPROACHES & ENABLING TECHNOLOGIES	CONFERENCE ROOM 4: ADVANCES IN MEDICINAL CHEMISTRY, DRUG DESIGN	CONFERENCE ROOM 5: THERAPEUTIC STRATEGIES, ENABLING TECHNOLOGIES & BIOMARKER DEVELOPMENT	CONFERENCE ROOM 6: BRIDGING THE GAP BETWEEN AUTOMATION & DIGITALISATION THROUGH FAIR & DIGITAL TRANSFORMATION	CONFERENCE ROOM 7: SMART MANUFACTURING & ROBOTICS
<p>Using AI Discovery Strategies For Rare Disease</p> <ul style="list-style-type: none">• Healx is a techbio company that utilizes artificial intelligence to discover drugs, with a primary focus on uncovering treatments for rare diseases. This presentation will delve into our approach to drug discovery, shedding light on our advancements in pinpointing new mechanisms in rare diseases and potential new treatments <p>EMMA DAVIES, Associate Director, Healx</p>	<p>Leveraging AI For Arrayed CRISPR Screening For Target Identification</p> <ul style="list-style-type: none">• We have developed an arrayed CRISPR screening platform for primary cell models. Embedding AI and machine learning approaches into that platform allows us to mine of knowledge graphs to generate hypotheses that can then be validated using CRISPR, as well as separate distinct phenotypes in CRISPR screens with imaging endpoints <p>ULRIKE KUNZEL, Associate Principal Scientist, AstraZeneca</p>	<p>Impact Of Secondary Pharmacology Data In Drug Discovery Phase: Alleviate The Risk Of Clinical Adverse Effects</p> <p>How to minimize the risk of severe clinical adverse reactions and failure due to unwanted pharmacological properties prior to reaching the intended patient population through:</p> <ul style="list-style-type: none">• The use of in silico platforms, combined to• AI-assisted text mining tool,• Drug off-target pharmacology and• Clinical pharmacokinetics <p>BERENGERE DUMOTIER, Associate Director, Novartis</p>	<p>A Patient-First Approach To Discovery Of Antibodies Against Neurodegenerative Diseases</p> <ul style="list-style-type: none">• Alchemab's goal is to use the power of human immune system to identify disease-relevant targets as well as antibodies which can fight complex diseases. By surveying B cell receptor repertoires of resilient subjects using Next Generation Sequencing, bioinformatics, proteomics and phage display, we identify antibodies and targets to validate in the disease setting. Our platform is deliberately target-agnostic and we apply this novel approach to find first-in-class treatments for neurodegenerative diseases and cancer <p>PAULINA KOLASINSKA-ZWIERZ, Principal Scientist, Alchemab Therapeutics</p>	<p>Panel Discussion: Automation & Robotics In Drug Discovery & Development – Where Are We Now?</p> <p>Moderator: GEORGIOS MAVRAKIS, Senior Associate Scientist, Johnson & Johnson</p> <p>Panellists:</p> <p>PAOLA FERRINI, High Throughput Automation Investigator, GSK</p> <p>NIKOLAOS PAPAKOSTAS, Professor, University College Dublin</p> <p>OLIVER PETER, President, SiLA Consortium</p>	<p>Panel Discussion: Navigating The Future Of Manufacturing: Insights On Smart Manufacturing And Industry 4.0</p> <p>Moderator: REKHA LAKSHMANAN, Global Head Of Data Office, AstraZeneca</p> <p>Panellists:</p> <p>DALVIN DEOL, Automation and Modelling Expert, GSK</p> <p>STEVEN DRIVER, Global Energy Leader, Sanofi</p> <p>ARNDT NEUES, Industry Sales Manager, Omron</p>

12:10	<div>LUNCH BREAK</div>	<div>1-2-1 Meetings x3</div>	<div>Poster Displays</div>
-------	------------------------	---	---

CONFERENCE ROOM 1: IDENTIFICATION & VALIDATION OF NOVEL TARGETS	CONFERENCE ROOM 2: IDENTIFICATION & VALIDATION - TARGETED PROTEIN DEGRADATION	CONFERENCE ROOM 3: ADVANCED SCREENING APPROACHES & ENABLING TECHNOLOGIES	CONFERENCE ROOM 4: ADVANCES IN MEDICINAL CHEMISTRY, DRUG DESIGN	CONFERENCE ROOM 5: THERAPEUTIC STRATEGIES, ENABLING TECHNOLOGIES & BIOMARKER DEVELOPMENT	CONFERENCE ROOM 6: BRIDGING THE GAP BETWEEN AUTOMATION & DIGITALISATION THROUGH FAIR & DIGITAL TRANSFORMATION	CONFERENCE ROOM 7: SMART MANUFACTURING & ROBOTICS
<p>Track Chair: RAN FURMAN, Director of Discovery and Preclinical, Neurim Pharmaceuticals</p>	<p>Track Chair: TAKHAR KASUMOV, Associate Professor of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University</p>	<p>Track Chair: CHANNABASAVAI AH GURUMURTHY, Professor and Director, University of Nebraska Medical Center</p>	<p>Track Chair: BARTOSZ BARANOWSKI, Senior Expert Data Science, Novartis</p>	<p>Track Chair: AURELIE LE FEUVRE, Senior Principal Scientist, BenevolentAI</p>	<p>Track Chair: STEVE SWAN, Lab Value Team Business Lead, Organon</p>	<p>Track Chair: RAUL V. RODRIGUEZ, Vice President, Woxsen University</p>
<p>“Druggability” Reconsidered: Difficult Targets In Small Molecule Drug Discovery</p> <ul style="list-style-type: none">• Disease relevance and druggability of novel targets rarely match. However, new drug mechanisms and modalities have challenged our current view on “undruggable targets”. We will discuss how to leverage on the right lead finding strategy to address also difficult targets with small molecules <p>IOLANDA MICCO, Head of Discovery Chemistry, Axxam</p> <div></div>	<p>Integrated Drug Discovery For Protein Degraders And Molecular Glues</p> <ul style="list-style-type: none">• Targeted protein degradation offers promise for previously undruggable targets. NUVISAN's integrated protein degradation platform accelerates degrader discovery with a) state-of-the-art PROTAC and glue profiling technologies, b) efficient synthesis (>100 degraders/ day) combined with direct-to-biology approaches, c) POI, E3 ligase and respective binder identification. This comprehensive solution supports the drug discovery efforts from binder finding all the way to clinical degrader candidates <p>YANSONG WANG, Scientist II Medicinal Chemistry, Nuvisan</p> <div></div>	<p>Phenotype-Guided Drug Design: From Image To Structure</p> <p>High Content Imaging (HCI) has transitioned from being primarily a tool for confirmatory assays to a cornerstone in high-throughput drug discovery. This shift has been propelled by significant advances in computational capabilities. In our talk, we will cover:</p> <ul style="list-style-type: none">• Employing CellPainting and AI analytics for efficient screening of large compound libraries• Image-guided design of new molecules using generative AI approaches• Join us for our presentation on the newest approach in Lead Optimization and Library Design, and be at the forefront of the blooming HCS field <p>KRZYSZTOF RATAJ, Cheminformatics Data Scientist, Ardigen</p> <div></div>	<p>Predicting PK From Limited ADME Data Using Deep Learning</p> <p>This presentation will:</p> <ul style="list-style-type: none">• Outline a unique deep learning imputation method that can learn from sparse data• Provide a case study demonstrating that this approach can predict PK parameters with state-of-the-art accuracy using a high-quality data set of rat PK and sparse data for nine in vitro ADME properties• Demonstrate the application of this method to an ongoing anti-infective drug discovery project <p>MATTHEW SEGALL, Chief Executive Officer, Optibrium</p> <div></div>	<p>Proteomics Solutions For Biomarker Discovery And Monitoring In Tissue And Biofluid Samples</p> <ul style="list-style-type: none">• State-of-the-art unbiased mass spectrometry workflows for biomarker discovery and monitoring in tissues and biofluids• NULISA panels to provide complementary insights on inflammation and neurodegeneration• Case study: Profiling of matched CSF and plasma samples to unveil signatures of aging and early cognitive decline <p>YUEHAN FENG, Senior Director, Application Sciences, Biognosys</p> <div></div>	<div><p><i>Delegates welcome to attend co-located sessions</i></p></div>	<div><p><i>Delegates welcome to attend co-located sessions</i></p></div>

BROCHURE CONTENTS

Welcome

Attendees

Sponsors

Session Topic Areas

Programme Highlights

Confirmed Speakers

Agenda: Day One

Agenda: Day Two






Venue Information

Networking Drinks

Oxford Global Plus Pass

Forthcoming Events

Book Now

13:30	<div>CONFERENCE ROOM 1: IDENTIFICATION & VALIDATION OF NOVEL TARGETS</div> <div>Cryo-Electron Microscopy Is Revolutionizing Rational Drug Discovery Pipelines<ul style="list-style-type: none">Cryo-EM is a powerful technique for high-resolution analysis of drug-target interactions. This talk will cover several studies, including CDK-activating kinase, ion channels, and GPCRs, where cryo-EM was employed for structure-based drug design</div> <div>IEVA DRULYTE, Senior Scientific Solutions Consultant, Thermo Fisher Scientific</div> <div></div>	<div>CONFERENCE ROOM 2: IDENTIFICATION & VALIDATION - TARGETED PROTEIN DEGRADATION</div> <div><i>Delegates welcome to attend co-located sessions</i></div>	<div>CONFERENCE ROOM 3: ADVANCED SCREENING APPROACHES & ENABLING TECHNOLOGIES</div> <div>High Throughput Screening Of The pH-Activated GPR65 And GPR68 Receptors<ul style="list-style-type: none">GPR65 & GPR68 are pH-activated receptors that have been implicated in cancer. EuroscreenFast has developed custom cell lines and assays for GPR65 & GPR68, and used these in a high-throughput screening campaign to identify a number of primary hits from a compound library. These can serve as potential starting points to develop drug candidates against each GPCR</div> <div>LAURENT MEEUS, Chief Scientist & Business Unit Director, EuroscreenFast</div> <div></div>	<div>CONFERENCE ROOM 4: ADVANCES IN MEDICINAL CHEMISTRY, DRUG DESIGN</div> <div>A Strategy For DEL-Hit Optimization - Case Study On p38a<ul style="list-style-type: none">DNA encoded library (DEL) screening is an excellent technology to screen billions of molecules. The optimization of DEL-hits can be challenging as some hits have higher molecular weights. To optimize these hits we have established a DEL-hit optimization strategy based on a hit fragmentation approach using ligand efficiencyIn this case study of p38a a DEL-hit optimization utilizing this strategy is shown</div> <div>ANDREAS SCHOOP, Head of Medicinal Chemistry, WuXi AppTec</div> <div></div>	<div>CONFERENCE ROOM 5: THERAPEUTIC STRATEGIES, ENABLING TECHNOLOGIES & BIOMARKER DEVELOPMENT</div> <div><i>Delegates welcome to attend co-located sessions</i></div>	<div>CONFERENCE ROOM 6: BRIDGING THE GAP BETWEEN AUTOMATION & DIGITALISATION THROUGH FAIR & DIGITAL TRANSFORMATION</div> <div>Solution Provider Presentation</div> <div>Senior Representative, Chemspeed Technologies</div> <div></div>	<div>CONFERENCE ROOM 7: SMART MANUFACTURING & ROBOTICS</div> <div>QC Microbiological Lab Of The Future - Automated, Rapid, Flawless And Paperless<ul style="list-style-type: none">In this presentation, we will address the current challenges of QC Microbiology and their related problems. We will introduce a solution (Growth Direct System) that will address those challenges holistically and providing a level of automation, never seen before in QC MicrobiologyIn a case study, we will look into two examples of an instrument implementation with a LIMS, that provided even further level of flawless automation</div> <div>IVAN MUHVIC, Field Validation Specialist, Rapid Micro Biosystems</div> <div></div>
13:50	<div>Panel Discussion: Landscape Of Drug Discovery And Impact Of AI<ul style="list-style-type: none">Hype or RealityDemonstrating utilityDiscussion of when AI/ML failsCultural shift & adoption</div>	<div>Panel Discussion: Using Genomics And Genetic Data For Target Identification And Validation<ul style="list-style-type: none">Leveraging AI in CRISPR ScreeningBase EditingMultiple Gene KnockoutsComplex cell modelsAutomationEndpoint multiplexing</div>	<div>Emerging Genome Editing Technologies For Developing Animal Models<ul style="list-style-type: none">Many drug discovery research projects rely on use of genetically engineered animal models containing large sized gene knock-in modelsIn this session I will present a few emerging CRISPR technologies for designing and generating custom animal models useful for drug discovery research</div> <div>CHANNABASAVIAH GURUMURTHY, Professor and Director, University of Nebraska Medical Center</div>	<div>Panel Discussion: Accelerating DMTA Cycle<ul style="list-style-type: none">AI/MLAutomation - Chemical Libraries etcStructured based DesignData Analysis & Integration</div>	<div>Panel Discussion: Translational Challenges In Neuro-Immunology<ul style="list-style-type: none">How to speed up development, but manage riskImmunotherapies for neuroinflammation & neurodegenerationCorrelation, prediction, and surrogacy of biomarkers in neuroscience</div>	<div>Panel Discussion: Data As A Product<ul style="list-style-type: none">Automated data captureInterconnectivity & transparencyData Governance</div>	<div>Advanced Manufacturing Technologies For Mobile Robots<ul style="list-style-type: none">The potential of mobile collaborative robots for improving current manufacturing practices in personalised therapeuticsThe benefits and challenges of introducing robots in biologics are explored, including current practices, limitations, likely future practices, and the market outlookExperiments demonstrating the application of a mobile collaborative robot to perform three different routine tasks are presentedThe investigations highlight the potential of collaborative mobile robotic platforms for automating the routine tasks carried out within the biomanufacturing sector</div> <div>NIKOLAOS PAPAKOSTAS, Professor, University College Dublin</div>
14:10	<div>Moderator: JEFF MESSER, Director Analytics, GSK Panellists: GRAHAM DEMPSEY, Chief Scientific Officer, Quiver Bioscience DAVID BEARSS, Chief Executive Officer, Halia Therapeutics</div>	<div>Moderator: DAVIDE GIANNI, Senior Director, AstraZeneca Panellist: ULRIKE KUNZEL, Associate Principal Scientist, AstraZeneca DOMINIC HUSSEY, Senior Director, Sales, bit.bio</div>	<div>Applying High-Throughput Cellular Assay Technologies For On-Target And Off-Target Screening<ul style="list-style-type: none">Cellular target engagement technologiesUtilizing robotic platforms for safety liability testing</div> <div>JON LEA, Team Leader GSK</div>	<div>Moderator: GEORG RÜEDI, Senior Director, Chemistry Technologies, Idorsia Panellists: SIMONA COTESTA, Director Global Discovery Chemistry, Novartis GUIDO KOCH, Chief Executive Officer & Co-Founder, Amphilix AG VLADIMIR TALIBOV, Associate Principal Scientist, Sprint Bioscience AB</div>	<div>Panellists: JAMES OVERELL, Group Medical Director, Roche JOHAN LUTHMAN, Executive Vice President of R&D, Lundbeck JANET BROWNLEES, Senior Director, Merck Sharpe and Dohme</div>	<div>Panellists: REKHA LAKSHMANAN, Global Head Of Data Office, AstraZeneca CHARLY COULON, Head of Future Manufacturing Concepts, INVITE GmbH GEORG WUITSCHIK, Senior Principal Scientist, F.Hoffmann-La Roche</div>	<div>Digital Transformation Of CMC: DataFactories And Digital Twins<ul style="list-style-type: none">Overview of predictive toolbox development for crystallisation (CCS) and drug product (MCS+)Building the data fabric to support product and process developmentData factories and automated workflows to accelerate developmentChallenges & opportunities for industrial digital technologies in CMC</div> <div>ALASTAIR FLORENCE, Director, CMAC, University Of Strathclyde</div>

BROCHURE
CONTENTS

Welcome

Attendees

Sponsors

Session
Topic Areas

Programme
Highlights

Confirmed
Speakers

► Agenda:
Day One

Agenda:
Day Two



Venue
Information

Networking
Drinks

Oxford
Global
Plus Pass

Forthcoming
Events

Book Now

	<div>CONFERENCE ROOM 1: IDENTIFICATION & VALIDATION OF NOVEL TARGETS</div> <div>Chemogenomic Screens For Target Identification</div> <div><ul style="list-style-type: none">This talk will focus on the application of GSK's chemogenomic (CxG) screening platform to enable target identification as a stand-alone approach or alongside genetic screening. We will describe our CxG capability and its application in disease-relevant primary cellular systems, such as iPSC derived macrophages</div> <div>AMELIE JOFFRIN, Investigator, GSK</div>	<div>CONFERENCE ROOM 2: IDENTIFICATION & VALIDATION - TARGETED PROTEIN DEGRADATION</div> <div>Advancing Lead Generation Strategies For Targeted Protein Degradation</div> <div><ul style="list-style-type: none">Lead generation examplesValidation and mechanistic studiesEvolution of turning hits into leads</div> <div>DIANA ZINDEL, Associate Director, AstraZeneca</div>	<div>CONFERENCE ROOM 3: ADVANCED SCREENING APPROACHES & ENABLING TECHNOLOGIES</div> <div>Enabling DEL For Membrane Proteins With The Salipro Platform: Screenings, Characterisation & cryoEM For Challenging Drug Targets</div> <div><ul style="list-style-type: none">Many membrane proteins represent emerging drug targets known to be notoriously difficult to work withThe Salipro DirectMX® technology incorporates membrane proteins directly from cell membranes into lipid Salipro® nanoparticles, presenting new opportunities for de novo development of biologics and small molecule drugsWe will present our latest developments showcasing DEL screening using native GPCRs and ion channels</div> <div>ROBIN LÖVING, Chief Scientific Officer, Salipro Biotech</div>	<div>CONFERENCE ROOM 4: ADVANCES IN MEDICINAL CHEMISTRY, DRUG DESIGN</div> <div>AI And ML In Drug Discovery – Empowering People And AI Models</div> <div><ul style="list-style-type: none">The FAIRification of data (making data findable, accessible, interoperable and reusable) has been an important goal in recent years. Now we will focus on how we can maximize the benefits and get the most out of the data. We will look at interfaces that empower both humans and AI. This will enable LLM-based AI assistants to programmatically interact with user-defined data sources and draw conclusions that lead to new insights</div> <div>MANUEL STRITT, Head of Scientific Computing Drug Discovery, Idorsia Pharmaceuticals Ltd</div>	<div>CONFERENCE ROOM 5: THERAPEUTIC STRATEGIES, ENABLING TECHNOLOGIES & BIOMARKER DEVELOPMENT</div> <div>Advancements In Gene Therapy Approaches For The Treatment Of CNS Diseases</div> <div><ul style="list-style-type: none"></div> <div>NATHALIE CARTIER-LACAVE, Senior Vice President Neurobiology, Askbio</div>	<div>CONFERENCE ROOM 6: BRIDGING THE GAP BETWEEN AUTOMATION & DIGITALISATION THROUGH FAIR & DIGITAL TRANSFORMATION</div> <div>Digital Transformation Through Software Engineering - Our Journey Of Building A Custom ELN/LIMS Platform</div> <div><ul style="list-style-type: none">We spent many years on developing our in house data platform to manage all our research and development data - and ended up learning much more about data challenges beyond technology</div> <div>ELIAS HAGMANN, Senior Manager Data Science & Information Architecture, Molecular Partners AG</div>	<div>CONFERENCE ROOM 7: SMART MANUFACTURING & ROBOTICS</div> <div>Necrobotics 360: Shaping The Future Of Healthcare</div> <div><ul style="list-style-type: none">Necrobotics pioneers a healthcare revolution, integrating AI and robotics to advance patient care and diagnostics. Precision in procedures, from diagnosis to surgery, is enhanced. Ethical concerns are addressed through stringent regulations. Collaborative efforts aim to shape a future where AI and robotics harmonize, reshaping healthcare for all</div> <div>RAUL V. RODRIGUEZ, Vice President, Woxsen University</div>
14:30							
14:50	<div><div>AFTERNOON BREAK</div><div> 1-2-1 Meetings x3</div><div> Poster Displays</div></div>						
	<div>CONFERENCE ROOM 1: IDENTIFICATION & VALIDATION OF NOVEL TARGETS</div> <div>Application of ML/AI In Discovery In Target ID To Clinical Proof Of Concept</div> <div><ul style="list-style-type: none">Introduction to CONVERGE, the Verge platform used to identify novel targetsVerge's journey in ALS with PIKfyve small molecule inhibitorFuture direction and expansion for AI/ML application beyond drug discovery</div> <div>IRENE CHOI, Head of Drug Discovery, Verge Genomics</div>	<div>CONFERENCE ROOM 2: IDENTIFICATION & VALIDATION - TARGETED PROTEIN DEGRADATION</div> <div>Improved Hit Identification By Incorporation Of Counter Screening And Orthogonal Assays</div> <div><ul style="list-style-type: none">High-throughput screening focusing solely on primary assays often struggles to generate high quality hits due to compound interference. Here we present case studies demonstrating how a catalytically inactive counter screen and a thermal shift orthogonal assay effectively triage false positives and expedite high-quality hit identification</div> <div>XIANG YI, Senior Principal Scientist, Amgen</div>	<div>CONFERENCE ROOM 4: ADVANCES IN MEDICINAL CHEMISTRY, DRUG DESIGN</div> <div>New Opportunities For The Utilization Of The Sulfoximine Group in Medicinal Chemistry From The Drug Designer's Perspective</div> <div><ul style="list-style-type: none">Interest in sulfoximines for medicinal chemistry has increased substantially in recent years. This presentation highlights emerging trends and opportunities for drug designers for the utilization of the versatile sulfoximine group, such as in the construction of complex molecules, proteolysis targeting chimeras (PROTACs), antibody–drug conjugates (ADCs) or cyclic peptides</div> <div>ULRICH LÜCKING, Vice President, Head of Chemistry, FoRx Therapeutics AG</div>	<div>CONFERENCE ROOM 5: THERAPEUTIC STRATEGIES, ENABLING TECHNOLOGIES & BIOMARKER DEVELOPMENT</div> <div>Workshop: Overcoming The Blood Brain Barrier In The Delivery Of Therapeutics - Presentation 1: Beyond the Shuttle: Advances In Brain Delivery Of Biologics For The Treatment Of Neurodegenerative Diseases</div> <div><ul style="list-style-type: none">Here, we present data on Roche's Brainshuttle™ technology, from in vitro studies that shed light on the cellular mechanisms of transcytosis, to enhanced brain exposure in animal models and humans. We further demonstrate the versatility of our Brainshuttle™ in transporting different drug modalities including antibodies and anti-sense oligonucleotides to the CNS with a broad and homogeneous biodistribution</div> <div>URS LANGEN, Lab Head, Roche</div>	<div>CONFERENCE ROOM 6: BRIDGING THE GAP BETWEEN AUTOMATION & DIGITALISATION THROUGH FAIR & DIGITAL TRANSFORMATION</div> <div>Integration Of IPC Equipment Into MES To Enable Paperless Production</div> <div><ul style="list-style-type: none">We share a project-approach for connecting IPC devices to a MES with the aim to automate processes and eliminate paper. Presentation will cover situation at a pharmaceutical company, challenges faced and highlight the decisions taken. You will get insights into approach, understand GxP considerations and benefit from a lessons learned</div> <div>BIANCA BRENNER, Head of MES Projects, Bayer MARKUS HUNGENBACH, Program Manager MES Global Program, Bayer</div>	<div>CONFERENCE ROOM 7: SMART MANUFACTURING & ROBOTICS</div> <div>End To End (E2E) Automated For Drug Product And Device Testing</div> <div><ul style="list-style-type: none">This talk introduces an end-to-end automated laboratory solution that enables 24/7 drug product and medical device testing in a GMP-compliant mannerThe system leverages advanced robotics and software platforms to develop fully automated workflows to drive major efficiency gains and meet the evolvingdemands of an increasingly diverse product portfolio</div> <div>GEORGIOS MAVRAKIS, Senior Associate Scientist, Johnson & Johnson</div>	
15:50							
16:10	<div>Discovery And Validation Of Potent Drug-Conjugates With Fast Tumor Penetration And Systemic Clearance</div> <div><ul style="list-style-type: none">The optimization of drug conjugates involves manipulating molecular size, valency, and pharmacokinetics to enhance therapeutic efficacy. This strategy impacts tumor penetration, renal clearance, and systemic exposure. Nanofitins, small affinity ligands (7 kDa), offer promise as selective tumor-targeting modules for drug conjugatesA demonstration study focusing on anti-EGFR Nanofitins reveals their rapid and profound tumor penetration in EGFR-positive xenograft models, attributed to their small size and monovalent format. Conjugation with monomethyl auristatin E toxin (MMAE) yields homogeneous Nanofitin-drug conjugates, showcasing significant efficacy in curative xenograft modelsThis approach highlights the potential of tailored drug conjugates in cancer therapy, leveraging molecular engineering for enhanced therapeutic outcomes</div> <div>SIMON HUET, Senior Scientist, Affilogic</div>	<div>Ethanol Impacts Hepatic Metabolism Via Altered Acetylation Dynamics In Mice</div> <div><ul style="list-style-type: none">Ethanol (EtOH) induces liver damage and alters metabolismThe acetylome dynamics method examined EtOH-induced hepatic injury in mice, revealing reduced turnover and elevated acetylation of mitochondrial proteins and histonesThese changes altered metabolism and induced oxidative stress</div> <div>TAKHAR KASUMOV, Associate Professor of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University</div>	<div>What CADD Approaches Are Really Impacting Drug Discovery?</div> <div><ul style="list-style-type: none">Prediction of binding, potency and selectivityKey role of water networks and lipophilic hotspotsHow to get FEP binding affinity prediction methods working well for GPCRsNew approaches for selectivityGetting the best from experimental structuresAI, AlphaFold2...</div> <div>JONATHAN MASON, Senior Research Advisor, Design for Drug Discovery</div>	<div>Presentation 2: Brainshuttle(TM) Technology In The Clinic: Trontinemab For Alzheimer's Disease</div> <div><ul style="list-style-type: none">Trontinemab is an anti-amyloid monoclonal antibody leveraging Brainshuttle(TM) technology., currently being tested in a Phase Ib/Ila trial. Pharmacodynamic data will be presented demonstrating how this novel way of penetrating the blood brain barrier manifests in the clinic</div> <div>GEOFFREY KERCHNER, Vice President, Global Head of Early Development – Neuroscience & Rare Diseases, Roche</div>	<div>Pioneering Digital Transformation In The Lab</div> <div><ul style="list-style-type: none">Roche's digitalization strategy for laboratories leverages an innovative software toolkit to enhance data management, standardize workflows, and boost efficiency. This presentation will explore the digital lab ecosystem, discuss benefits, and provide examples of recent workflow integrations and their unique challenges</div> <div>JAMIE CLIFTON, Senior Scientist, Roche</div>	<div>Democratization Of Lab Automation</div> <div><ul style="list-style-type: none">With our AC/DC* Lab [*Automation, Connectivity & Digitalization Concept] we are setting up a standardised Lab Automation Eco.System which will make plug and play automation become available and DIY Automation at almost light-speed possible</div> <div>TOM KISSLING, pRED Lab Automation Partner, F. Hoffmann La Roche Ltd</div>	

BROCHURE
CONTENTS

Welcome

Attendees

Sponsors

Session
Topic Areas

Programme
Highlights

Confirmed
Speakers

▶ Agenda:
Day One

Agenda:
Day Two

Venue
Information

Networking
Drinks

Oxford
Global
Plus Pass

Forthcoming
Events

Book Now

	CONFERENCE ROOM 1: IDENTIFICATION & VALIDATION OF NOVEL TARGETS	CONFERENCE ROOM 2: IDENTIFICATION & VALIDATION - TARGETED PROTEIN DEGRADATION	CONFERENCE ROOM 4: ADVANCES IN MEDICINAL CHEMISTRY, DRUG DESIGN	CONFERENCE ROOM 5: THERAPEUTIC STRATEGIES, ENABLING TECHNOLOGIES & BIOMARKER DEVELOPMENT	CONFERENCE ROOM 6: BRIDGING THE GAP BETWEEN AUTOMATION & DIGITALISATION THROUGH FAIR & DIGITAL TRANSFORMATION	CONFERENCE ROOM 7: SMART MANUFACTURING & ROBOTICS
16:30	Panel Discussion: Emerging Modalities & Overcoming Challenges <ul style="list-style-type: none">• Which target for which modality• Working towards predictability and ease of implementation<ul style="list-style-type: none">» Small Molecules» Antibodies» Oligonucleotides» RNA» Targeted Protein Degradation	Panel Discussion: Data Generation & Modelling For Drug Discovery <p>How FAIR is public data?</p> <ul style="list-style-type: none">• How can Pharma share data for model building without sharing IP?• Generating new therapeutics• Leveraging data sources with solid data foundations & model validation• Disease models based on advanced knowledge graphs	Natural Products In Modern Crop Protection Research <p>OLIVIER LOISELEUR, Senior Team Leader, Syngenta</p>	Presentation 3: Diligent Design Of Brainshuttle-Antisense Oligonucleotide Conjugates For Brain Delivery <ul style="list-style-type: none">• Antisense-oligonucleotides are a promising drug modality for the treatment of neurological disorders, but their administration via IT is limiting their broader clinical application. Peripheral delivery of ASOs to the CNS by conjugation to a Brainshuttle™ antibody is investigated <p>KERSTIN HOFER, Senior Scientist & Matrix Lead, Roche</p>	Bridging The Gap Between Warehouse Data And Equipment Data <ul style="list-style-type: none">• What hurdles need to be overcome to obtain the right network landscape and ultimately the right plumbing• Data flows from different devices to data lakes, combined into a data ocean• What is the essence of data collection to draw a reliable conclusion by iterative thinking <p>BART VAN LOON, Lab Information & Automation Specialist, MSD</p>	Roundtable: Overcoming The Challenges – Manufacturing The Next Generation Of Pharmaceutical Mobile Robots <p>Maintaining quality control</p> <ul style="list-style-type: none">• Meeting regulatory requirements throughout the robotic manufacturing process• Flexibility and scalability• Integrating robotic systems into existing manufacturing infrastructures
16:50	Moderator: DIANA ZINDEL, Associate Director, AstraZeneca Panellist: GIOVANNI SPAGNOLLI, Chief Technology Officer, Sibylla Biotech OLIVIER BUGAUD, Senior Scientist Assay Development, Galapagos	Moderator: RICHARD LEWIS, Director Data Science, Novartis Panellists: CK ONG, Director, Data Product, GSK IRENE CHOI, Head of Drug Discovery, Verge Genomics	Scale Up Your Experts, Skill Up Your Data: Augmented Interactive Design In Fragment-Based Drug Discovery <ul style="list-style-type: none">• This talk will explore ideas around Augmented Interactive Design as a strategy that integrates AI-driven approaches with human expertise – thus adding scale to the tradition of carefully handcrafted design <p>CARL POELKING, Associate Director, Astex</p>	Panel Discussion: Challenges Of The Blood Brain Barrier In Neuroscience Drug Development <ul style="list-style-type: none">• BBB permeability• Structural complexity• Translation of models into effective treatments <p>Moderator: GEOFFREY KERCHNER, Vice President, Global Head of Early Development – Neuroscience & Rare Diseases, Roche Panellists: KERSTIN HOFER, Senior Scientist & Matrix Lead, Roche URS LANGEN, Lab Head, Roche</p>	E2E Strategy On Digital And PAT Capabilities In Drug Substance Manufacturing <ul style="list-style-type: none">• Digital Strategy• PAT (Process Analytical Technology) introduction at-scale and real-time data generation• Data management• Data analytics (data democratization, self-service analytics, advanced analytics, digital twin, ML/AI)• Process automation & advanced process control <p>RAQUEL DE PADUA FERNANDES SILVA, Senior Associate Scientist & VALENTINE TUYISHIME, Digital & Technology Lead, Johnson & Johnson Innovative Medicine</p>	Co-Moderators: NIKOLAOS PAPAKOSTAS, Professor, University College Dublin CHARLY COULON, Head of Future Manufacturing Concepts, INVITE GmbH
17:10	End of Day 1 & Speed Networking					

BROCHURE
CONTENTS

Welcome

Attendees

Sponsors

Session
Topic Areas

Programme
Highlights

Confirmed
Speakers

Agenda:
Day One

▶ Agenda:
Day Two

Venue
Information

Networking
Drinks

Oxford
Global
Plus Pass

Forthcoming
Events

Book Now

DAY TWO

DISCOVERY EUROPE ROUNDTABLE DISCUSSIONS

Roundtable Discussion 1: Integration Of DEL For The Optimisation Of HITS
Moderator: SANNE GLAD, Scientific Director, Amgen Research Copenhagen

Roundtable Discussion 2: Digital Biomarkers In Neuroscience Clinical Development

- Current context of use of digital biomarkers
- Regulatory path for digital biomarkers
- Can we speed up the development and implementation of digital biomarkers?

Moderator: JOSÉ LUIS MOLINUEVO, Vice President & Head of Experimental Medicine, Lundbeck

AUTOMATE EUROPE ROUNDTABLE DISCUSSIONS

Roundtable Discussion 3: EU Research Project TraceBot: AI Enabled Built-In Verification And Audit Trail Generation

- Short video demonstration: Robot-systems copying self-awareness from humans in sterility testing
- You recognize if your cup of coffee slips through your fingers... even though no SOP tells you to check this
- Future robotic systems will have the same “built in” capability of verification and failure detection
- Discussion: Will this revolutionize the way we qualify automated systems?

Moderator: CHARLY COULON, Head of Future Manufacturing Concepts, INVITE GmbH

Roundtable Discussion 4: Assessing The Growing Need For Laboratory Automation To Accelerate Drug Discovery Processes With Industry 4.0

- Examining the key factors of innovation and speed for developing new drugs and therapies
- Exploring strategies for applying low-code development, digital representation, and automated workflows
- How will industry 4.0 accelerate lab automation and drive faster drug discovery?

Moderator: PRANAV BENDE, Senior Robotics Engineer, National Institutes of Health

CONFERENCE ROOM 1: EMERGING MODALITIES: TARGETED PROTEIN DEGRADATION

Track Chair: MARKUS SCHADE, Principal Scientist, AstraZeneca

Track Keynote: Folding Interference: A Novel Strategy To Induce Selective Target Degradation In Vitro And In Vivo

- Folding interference is a novel strategy to achieve the selective degradation of a target protein. The discovery of small molecules acting with such a mechanism is made possible by Sibylla's proprietary platform. New in vitro and in vivo results of folding interfering degraders targeting Cyclin D1 will be presented

GIOVANNI SPAGNOLLI, Chief Technology Officer, Sibylla Biotech

CONFERENCE ROOM 2: MOLECULAR DRUG DESIGN & HIT FINDING/OPTIMISATION

Track Chair: ERIC GOEDKEN, Senior Principal Scientist, AbbVie

Track Keynote: Implementation Of Physics Based Insilico Tools To Drive Design

- The DMTA cycle (Design, Make, Test, Analyze) represents the iterative workflow to optimize hits towards clinical candidates. We discuss the design aspect of the DMTA cycle and illustrates an example from KRASG12C. We employed a QM-based workflow to predict ligand-strain and compute 3D-PSA, as an indicator of passive permeability

SIMONA COTESTA, Director Global Discovery Chemistry, Novartis

CONFERENCE ROOM 3: DRUG DISCOVERY FOR NEURODEGENERATIVE DISEASES

Track Chair: DAVID BEARSS, Chief Executive Officer, Halia Therapeutics

Track Keynote: Accelerating Target Discovery In Neuroscience

- Identification of the next generation of neurodegeneration drug discovery targets beyond aggregated proteins is a challenge in the field. In silico approaches to harness the array of omics datasets now available may have a key part to play in target identification. The talk will include examples of how MSD Neuroscience are using these approaches

JANET BROWNLEES, Senior Director, Merck Sharpe and Dohme

CONFERENCE ROOM 4, PART 1: DATA-DRIVEN MODELLING & DATA ANALYTICS FOR DRUG DISCOVERY & DEVELOPMENT

Track Chair: VIRGINIE BRUN, Senior Scientist I, Novartis

Track Keynote: FAIR Data Principles In Pharmaceutical R&D

- Vision of a transparent, robust architecture that seamlessly manages data from capture to consumption in a consistent manner
- Key guiding principle is to ensure the data within it is FAIR (findable, accessible, interoperable and reusable) and this requires master data entity management; high quality and well managed metadata; and consistent reference data and standard ontologies
- This will eventually deliver re-usable data models and data design to facilitate reuse and maximise the value of data as an asset
- I will discuss how Information Architecture is central piece to the success of the project and beyond

CK ONG, Director, Data Product, GSK

Predicting ADME/PK Properties For Targeted Protein Degraders

- Most TPDs fall outside of Lipinski's rule of five, raising the question of the applicability of traditional in silico ADME/PK models. We will address the performance of existing models on TPDs, and how to best leverage small TPD ADME/PK datasets

GREGORI GEREBTZOFF, Director, Novartis

Toward Automation Of Molecular Optimization

- Exscientia's mission is to encode and automate drug discovery. Humans are great at formulating problems but computers are inherently better positioned to solve complex optimization problems in high-dimensional search spaces. We present our approach of encoding molecular design using generative design, cheminformatics, biophysics as well as active learning

DANIEL SEELIGER, Head of Small Molecule Design, Exscientia

Translational Tools For Predictability In Neuroscience Diseases

- Predictive validity of animal models within neuroscience
- Correlating exposure to efficacy and adverse events (PK/PD)
- Reproducibility of preclinical studies

MORTEN GRUNNET, Vice President & Head of Neuroscience, Lundbeck

AI Chatbots & Biology: Generative AI And Knowledge Graphs For Frictionless Information Access

- Join us for an engaging session where we delve into the transformative power of SEND (Standard for Exchange of Nonclinical Data), knowledge graph databases, LLMs, and advanced computational techniques in enhancing data discoverability and utility

PATRIK KAGELID, Data Engineer, AstraZeneca

QUANTROseq®, A Transcriptomic Based Drug Discovery Platform To Identify Inhibitors And Degraders Of Transcription Factors And Cell Signaling Regulators

- QUANTROseq®, an innovative platform able to identify new degraders of transcription factors and cell signaling regulators by systematically matching transcriptional fingerprints produced by drug candidates with the ones obtained by controlled acute degradation of the target of interest

ARIANNA SABÒ, Head of R&D, Quantro Therapeutics GmbH

Design Principles For Balancing Lipophilicity And Permeability In Beyond Rule Of 5 Space

- An analysis of ab initio predicted and measured physicochemical properties of oral beyond Rule of 5 drugs revealed an overlapping property space with Ro5 drugs. We introduce neutral TPSA as a novel design principle that increased in the lead optimization campaigns of three first in class de novo designed bRo5 drugs

HENRIK MÖBITZ, Associate Director, Novartis

Functional Genomics For Next Generation CNS Therapeutic Discovery

- Our functional genomics platform translates the language of the brain into machine-readable signals, integrating human cell-based models, all-optical electrophysiology, and AI/ML
- We quantify neuronal changes in disease, creating therapeutics that normalize altered behavior
- We are mapping cellular dysfunction at genome scale to accelerate/improve the design of next generation CNS therapeutics

GRAHAM DEMPSEY, Chief Scientific Officer, Quiver Bioscience

High-Throughput Automation To Aid Modelling in Drug Development

- We present why and how HT Automation is used in drug development at GSK to aid modelling. After summarising some of the advantages of the use of automation and models, we show, through few case-studies, how the two disciplines can complement each other and be applied in the pharmaceutical industry

PAOLA FERRINI, High Throughput Automation Investigator, GSK

MORNING BREAK



1-2-1 Meetings x4



Poster Displays

BROCHURE CONTENTS

Welcome

Attendees

Sponsors

Session Topic Areas

Programme Highlights

Confirmed Speakers

Agenda: Day One

▶ Agenda: Day Two

Venue Information

Networking Drinks

Oxford Global Plus Pass

Forthcoming Events

Book Now

14:00	<div>CONFERENCE ROOM 1: EMERGING MODALITIES: TARGETED PROTEIN DEGRADATION</div> <div>Track Chair: ULRIKE KUNZEL, Associate Principal Scientist, AstraZeneca</div> <div>Development Of Potent And Selective Disulfide Constrained Peptide Binders Against The E3 Ubiquitin Ligase ZNRF3<ul style="list-style-type: none">Disulfide constrained peptides (DCPs) show great potential as templates for drug discovery. We designed DCP phage libraries to enable the discovery of ligands against disease-causing proteins of interest. Using the libraries we developed DCPs that promote Wnt signaling activity via inhibiting a membrane bound E3 ubiquitin ligase ZNRF3XINXIN GAO, Principal Scientific Manager, Genentech</div>	<div>CONFERENCE ROOM 2: MOLECULAR DRUG DESIGN & HIT FINDING/OPTIMISATION</div> <div>Track Chair: IRENE CHOI, Head of Drug Discovery, Verge Genomics</div> <div>Discovery Of In Vivo Active, Small-Molecule IL17A Antagonists With Efficacy Equivalent To Anti-IL17<ul style="list-style-type: none">Dysregulation of IL17A drives numerous inflammatory disorders with anti-IL17A inhibition proven as an effective treatmentOral anti-IL17 therapies are an attractive alternative optionI will discuss discovery of novel small molecule IL17A inhibitors, identified via a DNA-encoded library screen and their optimization to in vivo efficacious inhibitorsERIC GOEDKEN, Senior Principal Scientist, AbbVie</div>	<div>CONFERENCE ROOM 3: DRUG DISCOVERY FOR NEURODEGENERATIVE DISEASES</div> <div>Track Chair: DAVID BEARSS, Chief Executive Officer, Halia Therapeutics</div> <div>Cellomics Platform Using Patient-Derived iPSC-Neurons-Based Screenings For Drug Discovery<ul style="list-style-type: none">Automated cell culture system coupled to an automated imagingRapid neuronal differentiation protocol using Neurogenin-2 (NGN2) and small molecule based neural precursor cellsFDA-approved (n=1430) compound repurposing screening strategy for therapeutic discoveryArrayed large scale CRISPR-activation screening in iPSC-neuronASHUTOSH DHINGRA, Staff Scientist, German Center for Neurodegenerative Diseases</div>	<div>CONFERENCE 4, PART 2: AUTOMATION WITH AI/ML & ROBOTICS TOOLS IN DRUG DISCOVERY & DEVELOPMENT</div> <div>Track Chair: OLIVER DE PEYER, Director, Automation Scientist, MeiraGTx</div> <div>End To End (E2E) Automation Of Analytical Workflows<ul style="list-style-type: none">In this presentation we will show how we connected and interfaced between Imprivata, Genedata Biologics, Chromeleon CDS, Liquid Handling Systems and an ELN to develop end to end automation of analytical workflowsFELIX STEMMER, Senior Scientist II, Novartis</div>
14:20	<div>TRACK 1, PART 2: ANIMAL MODELS FOR DISEASE, ORGAN MODELLING - ORGANOID BASED DISCOVERY & ORGAN ON CHIP DEVELOPMENT</div> <div>Integrating In Vitro Data Into Mechanistic Modelling For Prediction And Interpretation Of PKPD And Anti-Tumour Activity Of Irreversible TKIs<ul style="list-style-type: none">PKPD modelling can establish a link between compound concentrations, pharmacodynamic effect, and anti-tumour activity to support decision-makingA case study on building a model integrating different types of in vitro data for irreversible TKIs is presented, focusing on target engagement requirements for FIH dose selection and interpretation of clinical dataADRIANA SAVOCA, Associate Director, Translational PKPD, AstraZeneca</div>	<div>CONFERENCE ROOM 2: MOLECULAR DRUG DESIGN & HIT FINDING/OPTIMISATION</div> <div>Discovery Approaches In The mGlu Allosteric Modulators Field Both On Early Discovery Up To Clinical Development<ul style="list-style-type: none">Allosteric modulators of mGluR1-8 have been shown to offer an attractive strategy to develop small molecule therapeutics that readily cross the blood-brain barrierWe report our historical contribution with an highlight on technologies which enabled the discovery and the development of novel ligands and innovative drug candidatesJEAN-PHILIPPE ROCHER, Head of Discovery, Chemistry, Neurosterix</div>	<div>CONFERENCE ROOM 3: DRUG DISCOVERY FOR NEURODEGENERATIVE DISEASES</div> <div>Specific Neuronal Subtypes And Co-Cultures From hiPSC For Modelling Neurodegeneration<ul style="list-style-type: none">This presentation highlights iPSC-derived neurons in Alzheimer's drug screening, emphasizing the significance of selecting appropriate neuronal subtypes for Tau aggregation. It also explores the potential of co-culture in vitro systems with neurons, astrocytes, and microglia for effective drug screeningJULIAN RÖWE, Senior Scientist, AbbVie</div>	<div>CONFERENCE 4, PART 2: AUTOMATION WITH AI/ML & ROBOTICS TOOLS IN DRUG DISCOVERY & DEVELOPMENT</div> <div>A Direct-To-Biology Approach To Drug Discovery<ul style="list-style-type: none">Presentation of a high-throughput synthetic platform enabling the rapid biological evaluation of compound libraries without the need for purificationUse of automated liquid handling robotics to improve the efficiency of our nanoscale synthetic platformJULIE FOURNIER, Senior Scientist, GSK</div>
14:40	<div>Brain Organoids In Therapeutic Development</div> <div>Patient-derived brain organoids can revolutionize CNS drug discovery<ul style="list-style-type: none">RTT patient-derived organoids show a functional disease-linked phenotype that can be quantified in an unbiased manner across multiple distinct endpointsPhenotypic screening identified HDACs and AChE as potential therapeutic targetsDonepezil produced a robust, and reproducible dose-dependent rescue of the RTT functional phenotype (FLIPR and MEA electrophysiology) at relevant estimated brain concentrations and pharmacodynamic activityDonepezil is advancing to a Phase 2 clinical trial in RTT patients with a differentiated mechanism of action from DAYBUE (trofinetide), the first approved treatment for Rett syndromeROBERT FREMEAU, Chief Scientific Officer and Founder, BrainStorm Therapeutics</div>	<div>Solving Centuries-Old Drug Discovery Challenges With Artificial Intelligence: Hope Vs Hype<ul style="list-style-type: none">Cost-effectiveness and improving efficacy/ safety in case of novel drugsGlobal multifaceted collaborationsCADD combined with mathematical modelling is a magic bulletAI-based model has a lot of potential to revolutionize drug R&DHybrid CADD- and AI- powered technology in case of novel predictive medicinePRASHANT GAHTORI, Professor, Graphic Era Hill University</div>	<div>Panel Discussion: Bringing Therapeutics To New Frontiers<ul style="list-style-type: none">Case studiesImplementation within the clinicNew modalities in CNS disease</div>	<div>HTE OS: An HTE-Workflow At Roche – Built From The Ground Up<ul style="list-style-type: none">High-Throughput Experimentation built for chemists with a focus on data flow and analysisVERA JOST, Principal Associate Scientist & GEORG WUITSCHIK, Senior Principal Scientist, F.Hoffmann-La Roche</div>
15:00	<div>Application Of Patient-Derived Microtumors In Drug Development<ul style="list-style-type: none">Patient-derived models enable the clinically relevant assessment of response to tailored therapy and/or novel treatment approachesI will introduce our platform of patient-derived microtumours and autologous tumour-infiltrating lymphocytes and present data from immunohistochemical analysis, immune cell profiling, and compound efficacy testing using PDM mono- and immune-cell co-culturesEILEEN WEGNER, Research Associate, NMI</div>	<div>Delegates welcome to attend co-located sessions</div>	<div>Panellists: MORTEN GRUNNET, Vice President & Head of Neuroscience, Lundbeck KERSTIN HOFER, Senior Scientist & Matrix Lead, Roche IRAIDA SORIA, Senior Innovation and Business Manager, UK Dementia Research Institute</div>	<div>Automating Chemistry With Custom Robotics<ul style="list-style-type: none">The presentation will cover how custom robotic solutions, both mechanical and software, can help increase the efficiency of the research by addressing the bottlenecks in a chemical synthesis workflow. It will go over some automated platforms developed in-house, to address some processes and go over the basic practices when involving custom robotics in the labPRANAV BENDE, Senior Robotics Engineer, National Institutes Of Health</div>
15:20	<div>Delegates welcome to attend co-located sessions</div>	<div>Delegates welcome to attend co-located sessions</div>	<div>Unlocking The Potential Of TREM2: VG-3927 As A Novel Therapeutic For Alzheimer's Disease<ul style="list-style-type: none">Hypofunction of the microglial TREM2 receptor increases the risk of Alzheimer's disease. We show that the small molecule TREM2 agonist VG-3927 is capable of favorably modulating microglia activation and instructing a broadly neuroprotective profile across preclinical model systemsBORISLAV DEJANOVIC, Director – Translational Sciences & External Innovation, Vigil Neuroscience</div>	<div>Automation And Digitalisation In Target Discovery</div> <div>ASMITA AGRAWAL, Group Manager, Novo Nordisk</div>
15:40	End of Congress			

BROCHURE CONTENTS

Welcome

Attendees

Sponsors

Session Topic Areas

Programme Highlights

Confirmed Speakers

Agenda: Day One

▶ Agenda: Day Two

Venue Information

Networking Drinks

Oxford Global Plus Pass

Forthcoming Events

Book Now

Be Part of Something Exceptional



Messe Congress Center Basel
Messepl. 25, 4058
Basel, Switzerland

Discovery Europe will be held at the Congress Center Basel, Switzerland’s largest congress centre in terms of surface area. Nestled in the heart of the vibrant city, the venue stands as a beacon of excellence for hosting extraordinary events.

Beyond the impressive architecture and world-class amenities, the Congress Center Basel is strategically located, providing easy access for those coming from across the globe. The surrounding area boasts a rich tapestry of cultural attractions, fine dining establishments, and luxury accommodations, ensuring a memorable and well-rounded experience for all.

Oxford Global has secured a number of bedrooms at the Basel Marriott Hotel at a reduced conference rate:

Tuesday 21st May 2024 – £230, breakfast included

Wednesday 22nd May 2024 – £230, breakfast included

*Please note: £30 supplement is applicable for double occupancy

Should you wish to book a room, please email help@oxfordglobal.com. The final cut-off date to book bedrooms is Friday 3rd May 2024 – any bookings after this date are subject to availability and rates. Please note that any cancellations within 14 days prior to arrival are subject to cancellation charges.

<https://oxfordglobal.com/discovery/events/discovery-europe-2024#venue>



Please [click here to visit the hotel’s website](#) &
recieve more information



BROCHURE CONTENTS

Welcome

Attendees

Sponsors

Session
Topic Areas

Programme
Highlights

Confirmed
Speakers

Agenda:
Day One

Agenda:
Day Two

▶ Venue
Information

Networking
Drinks

Oxford
Global
Plus Pass

Forthcoming
Events

Book Now

Linkedin

X @OGConferences

Welcome

Attendees

Sponsors

Session
Topic Areas

Programme
Highlights

Confirmed
Speakers

Agenda:
Day One

Agenda:
Day Two

Venue
Information

► Networking
Drinks

Oxford
Global
Plus Pass

Forthcoming
Events

Book Now

DISCOVERY 2024 & AUTOMATE 2024 NETWORKING DRINKS

Wednesday 22nd May, 17:10
in the Exhibition Hall



We hope to see you there



12-MONTH CONTENT AND COMMUNITY ACCESS

Oxford Global PLUS Pass

Your Gateway to a Year of Unparalleled Knowledge-Sharing, Curated Experiences, and Global Networking!



Welcome to the future of life sciences engagement!

Effortless On-Demand Presentations

Immerse yourself in competitor case studies, groundbreaking market developments, and captivating high-level strategy discussions via our comprehensive library of on-demand presentations.

Beneficial Partnerships and Accelerated Learning

Foster invaluable partnerships for your business and accelerate high-end learning through peer-to-peer interactions. Participate in regular science exchange sessions, engaging group discussions, and dynamic in-person and online events that drive professional growth.

Year-Round Exclusive Insights

Unlock a world of exclusive insights throughout the year via our online platform. Enjoy unrestricted access to commentaries, interviews with Key Opinion Leaders (KOLs), industry reports, and curated market intelligence content, keeping you at the forefront of industry trends.

Elevate Your Event Experience

Event PLUS Pass includes catered lunches, ensuring you stay fuelled for vibrant discussions. You can also take the spotlight by showcasing your research projects through our eye-catching poster displays in the exhibition area – a prime opportunity for community engagement and invaluable feedback!

Your Passport to Unparalleled Access

Enjoy guaranteed entry to any Oxford Global event and online activities across all our brands. The PLUS Pass opens doors to a world of knowledge, connections, and opportunities for your continued success.

Full access across
all our Brands:

 **BIOLOGICS**

 **BIOMARKERS**

 **CELL & GENE**

 **DISCOVERY**

 **FORMULATION
& DELIVERY**

 **IMMUNO**

 **OMICS**

BROCHURE CONTENTS

Welcome

Attendees

Sponsors

Session
Topic Areas

Programme
Highlights

Confirmed
Speakers

Agenda:
Day One

Agenda:
Day Two

Venue
Information

Networking
Drinks

Oxford
Global
Plus Pass

Forthcoming
Events

Book Now

£499^{+VAT}

\$700^{+VAT}

Register Now 

To receive bespoke proposal for group packages
contact us at pluspass@oxfordglobal.com

*Please note: PLUS Passes are unavailable to service and
solution providers/vendor companies

Linked 

@OGConferences

DISCOVERY SERIES ACROSS 2024

Join leaders, experts and researchers, connecting global pharma, biotech and academia for high-level discussions on the latest innovations.



Organ Modelling & 3D Cell Culture 2024

18 - 19 March 2024 London, UK

Discovery Europe 2024

22 - 23 May 2024
Basel, Switzerland

Automate 2024

22 - 23 May 2024
Basel, Switzerland

Advanced Screening Approaches for Drug Target Identification & Validation: Online Symposium

23 October 2024 | GMT (UTC+0)

Discovery US 2024

07 - 08 November 2024
Boston, USA



Biologics Series

Proteins & Antibodies | Peptides | Oligonucleotides
Sustainability in Biologics | ADC Discovery & Development
Vaccines | Oligonucleotides Chemistry & Therapeutics

Biomarkers Series

Biomarkers | Biomarker & Precision Medicine
Precision Oncology

Cell & Gene Series

Gene Therapy Development
Cell Culture Advanced Therapy Development
Cell & Gene Therapy Manufacturing

Formulation & Delivery Series

Formulation & Drug Delivery
Inhalation & Respiratory Drug Delivery
RNA Therapeutics & Delivery

Immuno Series

Advances in Immuno-Oncology
Innate Killer Cells | Oncolytic Virotherapies | Targets &
Cell Types in Immuno-Oncology

Omics Series

Next Generation Sequencing
Single Cell & Spatial Analysis | Synthetic Biology
Next Generation Sequencing & Clinical Diagnostics
Digital PCR & Liquid Biopsies |
Synthetic Biology in Discovery & Therapeutics
Spatial Biology

Visit www.oxfordglobal.com/calendar/
to explore our diverse portfolio of events
across 2024.

Welcome

Attendees

Sponsors

Session
Topic AreasProgramme
HighlightsConfirmed
SpeakersAgenda:
Day OneAgenda:
Day TwoVenue
InformationNetworking
DrinksOxford
Global
Plus Pass► Forthcoming
Events

Book Now

Linkedin

X @OGConferences

OXFORD
GLOBAL
PLUS

12-MONTH CONTENT AND COMMUNITY ACCESS Oxford Global PLUS Pass

Oxford Global PLUS Pass includes
unrestricted access to all events
shown above and much more

Register Now

To receive bespoke proposal for group packages
contact us at pluspass@oxfordglobal.com